Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
22 August 2022Portfolio NewsImbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022
17 August 2022Portfolio NewsNanopath lands $10M for biosensing platform
17 August 2022Portfolio NewsPodimetrics Declares War on Diabetic Foot Amputations
10 August 2022Portfolio NewsArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10 August 2022SV NewsNumis adds International Biotech trust as ‘core buy’ on the back of rebound- 9 August 2022Portfolio NewsNanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Health
9 August 2022Portfolio NewsCerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease- 9 August 2022Portfolio NewsOn heels of Parkinson’s readout, Cerevance enters Alzheimer’s discovery deal with Merck
- 17 July 2022SV NewsUK has missed chances to prepare for future pandemics, says [Kate Bingham] ex-vaccines tsar
13 July 2022Portfolio NewsFDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer
6 July 2022Portfolio NewsNitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives- 30 June 2022Portfolio NewsRia Health Secures $18 Million Series A to Scale Online Alcohol Use Disorder Treatment
